Rezolute Inc. (RZLT)

[rosemountbomber]

Kiwi, I have to admit to being a bit confused here. Saw the comment that said that CST was not an endpoint used by the FDA, but checking various clinical studies they usually measure that at least as a secondary endpoint. Again, not sure if this is not a correct analogy, but looking at a Vabysmo study, it appeared that BCVA improved rather rapidly (less than 12 weeks by far), so the idea that here we would see visual improvement if study ran 12 months, I am not so sure about that. Anyway have lightened up here at 3.42.